Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →BioNTech will acquire CureVac in an all-stock deal worth approximately $1.25 billion, consolidating two of the world's leading mRNA companies and ending a…
BioNTech said on Thursday it would buy smaller rival CureVac in an all-stock deal valued at about $1.25 billion, as the German vaccine maker bets on…
BioNTech closed the CureVac acquisition on December 18, 2025; ~86.75% (195,341,219) of CureVac shares were validly tendered, and BioNTech expects to complete…
Source summaries from our enrichment pipeline; follow links for originals.
All 12 sources with sentiment breakdown →
BioNTech announced all-stock acquisition of CureVac in public exchange offer, ~$5.46 per CureVac share in BioNTech ADSs, total implied equity value ~$1.25B. Strengthens BioNTech's mRNA oncology platform and resolves prior patent litigation. Closed December 18, 2025. BioNTech completed the post-offer compulsory acquisition of the residual minority shares in January 2026, taking CureVac to 100% ownership and ending its public listing.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| BioNTech SE / CureVac N.V. (this deal) | 2025 | $1.2B | — |
| BioNTech SE / Duality Biologics (Suzhou) Co. Ltd. | 2023 | $1.7B | — |
| BioNTech SE / Biotheus Inc. (Pumai Biotechnology) | 2024 | $950M | — |
| BioNTech SE / Kite Pharma (Gilead Sciences) | 2021 | $250M | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
← Browse all deals · How we score deals
More: 2025 deals · BioNTech SE deals · Oncology deals